Orchestra Biomed Holdings Inc
Health Care
Orchestra Biomed Holdings Inc (OBIO) Stock News
The latest OBIO headlines and market coverage — 3 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
NANOBIOTIX annonce le règlement-livraison de son offre globale
NANOBIOTIX completed a global offering raising approximately $100 million in gross proceeds through the full exercise of the underwriters' over-allotment option. The offering included 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. The company plans to allocate proceeds toward JNJ-1900 development (less than 10%), Nanoprimer and other platforms (50-60%), and general corporate needs (30-40%), with sufficient runway through 2029.
- GlobeNewswire Inc.·
NANOBIOTIX Announces Closing of Global Offering
Nanobiotix, a late-clinical stage biotechnology company, announced the closing of its global offering on May 26, 2026, raising approximately $100 million in gross proceeds following the full exercise of underwriters' over-allotment option. The company issued 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. Net proceeds will be allocated toward advancing the Nanoprimer platform (50-60%), general corporate purposes (30-40%), and JNJ-1900 development (less than 10%). The company expects its financial resources to support operations into 2029.
- GlobeNewswire Inc.·
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.